Sign In
Buy TBPH
$15.92
+0.340 (+2.18%)
At Close: Jun 03, 2026
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
06:26pm, Monday, 26'th Feb 2024
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.21 per share a year ago.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:05pm, Monday, 26'th Feb 2024
Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million 1 Full Year 2023 Viatris Collaboration Revenue increased 18% to
Theravance Biopharma to Participate in an Upcoming Investor Conference
06:00am, Thursday, 22'nd Feb 2024
DUBLIN , Feb. 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston, M
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
06:00am, Wednesday, 14'th Feb 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after market close on
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
11:19am, Friday, 12'th Jan 2024
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street anal
Theravance Biopharma shares down on lung disease trial failure
08:37am, Friday, 05'th Jan 2024
Theravance Biopharma shares fell more than 20% after the company reported that its therapeutic for chronic obstructive pulmonary disease (COPD), a common lung disease, failed a clinical trial. Its
Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal
06:15am, Friday, 05'th Jan 2024
Theravance Biopharma Inc.'s stock TBPH, -0.60% tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with severe to very severe Chronic Obstructive Pulmon
7 Short-Squeeze Stocks That Are Screaming for Speculation
01:08pm, Sunday, 24'th Dec 2023
While the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. Rather, it's time to address this speculative p
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?
12:48pm, Thursday, 07'th Dec 2023
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
12:46pm, Wednesday, 08'th Nov 2023
Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.
Theravance: Positive Findings Boost Ampreloxetine Development
11:49am, Saturday, 09'th Sep 2023
Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's financials have shown improvement, with increased reve
Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold
10:12am, Friday, 08'th Sep 2023
Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation for COPD treatment, but isn't yet a long-term compou
DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss
11:25am, Tuesday, 08'th Aug 2023
Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.
Theravance Biopharma, Inc. (TBPH) Q2 2023 Earnings Call Transcript
09:33pm, Monday, 07'th Aug 2023
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Offic
